Introduction: Current guidelines recommend
hyperglycemia, but did not result in better glycemic control compared to non-insulin regimens. Rapid follow-up, more CDE visits, and a new diabetes diagnosis were predictors of successful glucose lowering. Patients with T2D and severe hyperglycemia, particularly those newly diagnosed, may be managed with noninsulin therapy.
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INTRODUCTION
Diabetes affects 25.8 million people (8.3%) in the USA. There were 1.9 million new cases diagnosed in 2010 alone [1] . While the diagnostic threshold for diabetes is an A1C
C6.5%, patients can present with severe hyperglycemia with A1C values reaching higher than 14%. Severe hyperglycemia may warrant specific and immediate treatment considerations to prevent acute complications, alleviate symptoms, and preserve beta cell function [2, 3] .
However, literature regarding the effectiveness of different treatment approaches to manage patients with non-emergent, severe hyperglycemia is limited.
The American Diabetes Association's (ADA) position statement on a patient-centered approach to the management of hyperglycemia in type 2 diabetes recommends that ''if a patient presents with significant hyperglycemic symptoms and/or has dramatically elevated plasma glucose concentrations ([300-350 mg/ dL), or an A1C C10-12%, insulin therapy should be strongly considered from the outset'' [3] . After symptoms are relieved and glucose levels are decreased, oral agents can be added and it may be possible to withdraw insulin, if preferred. This recommendation makes no distinction between newly diagnosed or drug-naïve patients and treated or established patients, and does not provide references or level of evidence. The American Association of Clinical Endocrinologists (AACE) algorithm for glycemic control recommends insulin therapy ± other agents for patients who present with an A1C [9% [4] . The recommendations state that ''for drug naïve patients with A1C levels [9%, it is unlikely that 1, 2, or even 3 agents (other than insulin) will achieve the A1C goal''. The algorithm does, however, suggest that treatment with combination non-insulin agents in drug-naïve patients who do not have symptoms may be sufficient. References or levels of evidence are not provided.
Although consensus statements suggest initiating insulin therapy, this is challenging in real-world practice. Successful insulin initiation requires time, resources, knowledge, proper dose titration, significant patient education and training, self-monitoring of blood glucose, and frequent follow-up [3] . In the primary care setting, many barriers exist, including time restraints, patient resistance, and lack of available resources and trained staff that make it difficult to initiate insulin therapy in a safe and effective manner.
The lack of sufficient evidence and the practical challenges posed by initiating insulin therapy support the need for further evaluation of treatment approaches to severe hyperglycemia in T2D patients. Therefore, the purpose of this study was to (1) 
MATERIALS AND METHODS

Study Design
This study was a retrospective observational cohort study of patients with a new or (defined as baseline) and followed through 1 year. Study data were collected and managed using a secure, electronic data capture tool [5] . 
Patient Population
Patients were included in the study if they were at least 18 years of age, had an A1C C12%
drawn from a UCH ambulatory clinic, and had a new or established diagnosis of type 2 diabetes.
Patients were excluded if they were less than 18 years of age, had type 1 diabetes, had no follow-up A1C reading within 12 months of initial presentation, were pregnant, were taking corticosteroids, or were diagnosed with stress-induced hyperglycemia, hyperglycemic hyperosmolar state, or diabetic ketoacidosis.
Study Cohorts
Clinical Response Cohorts
Patients were categorized into two cohorts based on a clinically meaningful improvement in glycemic control: (1) responders, defined as those patients who achieved an A1C B9% within 1 year of baseline, and (2) nonresponders, those who did not achieve an A1C
B9% within 1 year of baseline. A regression analysis was performed to identify what factors served as predictors of success in achieving an A1C B9%.
Initial Treatment Cohorts
Patients were stratified into two cohorts based on initial treatment medication prescribed within 1 month of baseline: (1) one or more non-insulin medications and (2) baseline to 12 months were compared between the cohorts using a last observation carried forward method.
Outcomes
The outcomes of the study were: (1) 
Results of the regression analysis to determine predictors of response are in Table 3 . A new diagnosis of diabetes, less days to first A1C follow-up, and more CDE visits were found to be predictors of response, while insulin treatment and number of endocrine clinic visits were not.
Changes in A1C from baseline are in Table 4 . The average A1C reduction in the total patient population was 3.5%. The non-insulin-treated cohort had a significantly greater reduction in A1C compared to the insulin-treated cohort (-4.5% vs -2.8%, p = 0.0011). Additionally, a significantly greater percentage of patients in the non-insulin cohort achieved an A1C B9% Table 6 . 
DISCUSSION
This study revealed that, although clinical guidelines recommend insulin therapy for patients with T2D presenting with severe hyperglycemia, only about two-thirds of patients in this study were initiated on an insulin-based regimen. Over one-third of patients were treated with non-insulin medications with 17.5% starting on a single non-insulin medication.
Regardless of adherence to guideline recommendations, 50.8% of the total population (n = 58) achieved an A1C B9% by the end of the year.
No correlation was found between any specific medication regimen and meaningful glucose response.
The current study provides useful insight into real-world use of insulin therapy in this patient population. Overall, insulin use in the responder group was lower than anticipated with only about half initiating insulin-based A1C glycosylated hemoglobin, CDE certified diabetes educator therapy. In addition, patients treated with insulin were actually less likely to achieve an A1C B9% and had less reduction in A1C from baseline compared to non-insulin-treated patients. Possible explanations for this lack of effect with insulin include inadequate dose titration or sub-optimal adherence. Patients prescribed insulin could be more challenging to treat or more likely to have experienced past treatment failures. This analysis did determine that more visits with a CDE was a predictor of successful Table 5 Comparisons between newly and previously diagnosed subjects [9, 10] . It is highly likely that, in this realworld clinical setting, several patients in the insulin-treated cohort did not have their insulin regimen intensified sufficiently to achieve successful glycemic control. Third, we defined glycemic response as achieving an A1C B9% within the first year. This A1C value does not meet the general target A1C recommended by the ADA, but was determined by the authors, a priori, to constitute a clinically meaningful A1C reduction in this severe hyperglycemia population. Fourth, subjects were regarded as an ''intent to treat'' population. If a patient started therapy with a non-insulin medication within 1 month of baseline, they remained in the non-insulin cohort throughout analysis, regardless of whether they later received insulin medications.
CONCLUSION
The results from this retrospective study show that a new diagnosis of diabetes, more visits with a certified diabetes educator, and fewer days to first follow-up A1C were predictors of success in achieving an A1C B9%, whereas insulin therapy was not. Furthermore, it was observed that insulin therapy did not lead to better A1C reductions or higher odds of achieving an A1C B9% compared to noninsulin regimens, regardless if the patient was newly diagnosed or had an established diagnosis. A new diagnosis of diabetes was a confounding variable. Meaningful glucose reductions were much more likely in newly diagnosed patients than those with established diabetes regardless of the treatment approach. Despite limitations, this study suggests that patients with T2D and severe hyperglycemia, particularly those newly diagnosed, may be able to be managed with non-insulin therapy.
Further randomized prospective studies are warranted to confirm this. 
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